site-logo
  • #ASCO22
  • LiquidHALLMARK®
  • Resources
    • Publications
    • News & Events
  • Patients
  • Company
    • About Us
    • News & Events
    • Careers
    • Contact Us
  • Request for Kits
    • LiquidHALLMARK®

Lucence Lights the Way at #ASCO22

Lucence presents promising new data of its NGS assay at the 58th Annual ASCO Meeting from June 3rd to 7th, 2022. Read More.

scroll-arrow
promise-gradient

Redefining the Future of Early Cancer Detection

The earliest signals of cancer are subtle. To detect cancer earlier, we are dedicated to building sensitive blood-testing technologies that profile cancer both accurately and affordably.

At Lucence, we are shaping this future of precision cancer care by capturing both sequence and cell information, all in one blood draw.

View Publications

Bringing Clarity to
Cancer Care Today

Physicians and patients urgently need information that drives their medical care. We currently deliver actionable insights through our proprietary technologies such as AmpliMark™. Real-world data has shown > 99% sensitivity of AmpliMark™ in detecting clinically relevant biomarkers for lung, breast, and blood cancers at 0.1% mutant allele frequency (MAF) limit of detection. Powered by AmpliMark™, our liquid biopsy test LiquidHALLMARK® is swift, simple and sensitive.

Learn more about LiquidHALLMARK®
Up arrow Back to top
Footer logo
Reach Us
3520 W Bayshore Road, Palo Alto, CA 94303 [email protected] (888) 582 3623
Subscribe for Updates

    Follow Us
    • facebook facebook-white
    • linkedin linkedin-white
    • twitter twitter-white

    © 2022 Lucence Health Inc. All rights reserved. All logos and trademarks are the property of Lucence or their respective owners.

    LiquidHALLMARK® | AmpliMark™ | Publications| Careers | About | Privacy

    Lucence announces publication of validation study for LiquidHALLMARK®, establishing the assay’s sensitivity.

    >